Company Overview and News

 
Reliance Power Limited - Shareholders meeting

2018-09-18 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
RPOWER 532939

 
Reliance Power looking to buy stressed power assets: Anil Ambani

2018-09-18 livemint
Mumbai: Reliance Power (RPower) is looking at inorganic expansion by buying stressed thermal power projects under resolution under the insolvency and bankruptcy code, said Reliance Group chairman Anil Ambani at the company’s annual general meeting (AGM) today.
RPOWER 532939

 
RPower eyes stressed thermal coal-based assets to boost growth

2018-09-18 moneycontrol
Reliance Power Chairman Anil Ambani today said the company is looking at inorganic growth through acquisition of stressed thermal coal-based projects.
RPOWER 532939

 
Reliance Power Limited - Updates

2018-09-05 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
RPOWER 532939

 
Reliance Power wants AP Government to scrap PPA on power project

2018-09-03 moneycontrol
Coastal Andhra Power Limited (CAPL), a subsidiary of Reliance Power Limited, has written a letter to the Andhra Pradesh government requesting it to cancel the power purchase agreement (PPA) it had signed for its 4000 MW power project, a non-starter, at Krishnapatnam.
RPOWER 532939

3
D-Street Buzz: Metal stocks shine with Tata Steel JSPL up 2-4%; ITI zooms 14%

2018-08-30 moneycontrol
The Sensex and the Nifty managed to regain some lost ground this Thursday afternoon with the Nifty50 down 12 points at 11,679 while the Sensex is down 22 points at 38,700.34
HINDCOPPER AMKD 500325 532939 UDBKL 500228 RELIANCE UBLS AMTEKAUTO 511389 VIDEOIND CADILAHC 532321 500470 RIGD UBLA GAILF RLNIY YESBANK RPOWER 513599 532648 YYBKY JSWSTEEL CDLYY BRK.A TTST TATASTEEL TATLY GAILY 501455 520077 GREAVESCOT

 
Reliance Power Limited - AGM/Book Closure

2018-08-27 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
RPOWER 532939

 
Reliance Power Limited - Shareholders meeting

2018-08-24 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
RPOWER 532939

 
Reliance Power unit wins $56 mn arbitration award

2018-08-24 freepressjournal.in
New Delhi : Reliance Power said its wholly-owned subsidiary Reliance Power Netherlands has won an international arbitration award of $56 million (Rs 390 crore) against Prestige Capital Holdings and Kokos Jiang.
RPOWER 532939

Related Articles

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

EKSO: Ekso Bionics Holdings Analysis and Research Report

2018-09-18 - Asif

Overview The company design, develop and sell exoskeleton technology to augment human strength, endurance and mobility. The company's exoskeleton technology serves multiple markets and can be used both by able-bodied users as well as by persons with physical disabilities. Ekso Bionics has sold, rented or leased devices that (a) enable individuals with neurological conditions affecting gait (stroke and spinal cord injury) to rehabilitate and to walk again and (b) allow industrial workers to perform heavy duty work for extended periods. Today, its medical exoskeleton, Ekso GT, is used as a rehabilitation tool to allow physicians and therapists to rehabilitate patients who have suffered a stroke or spinal cord injury. With its unique features designed specifically for hospitals and its proprietary SmartAssist software, Ekso GT allows for the early mobilization of patients, with high step count and high dosage treatments. The intent is to allow the patient’s central nervous syst...

AGRX: Agile Therapeutics Analysis and Research Report

2018-09-18 - Asif

Overview Agile Therapeutics is a forward-thinking women’s healthcare company dedicated to fulfilling the unmet health needs of today’s women. Twirla® and its other current potential product candidates are designed to provide women with contraceptive options that offer greater convenience and facilitate compliance. The company's lead product candidate, Twirla, also known as AG200-15, is a once-weekly prescription contraceptive patch that is at the end of Phase 3 clinical development. Since its inception in 1997, Agile Therapeutics has devoted substantial resources to developing Twirla, building its intellectual property portfolio, business planning, raising capital and providing general and administrative support for these operations. The company incurred research and development expenses of $14.4 million, $20.9 million and $25.6 million during the years ended December 31, 2017, 2016 and 2015, respectively. The company incurred research and development expenses of $2.4 milli...

Silicon Investor Message Boards

This table lists all message boards related to NSE:RPOWER / RELIANCE POWER LTD. on message board site Silicon Investor.

Starpower Starpower Starpower LSI: The New Internet Superpower? LSI: The New Internet Superpower? LSI: The New Internet Superpower?